Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

Abstract Background This study was designed to investigate the difference between brain metastases (BM) and non-brain metastases (non-BM) treated by osimertinib in advanced patients with an acquired EGFR T790M mutation after obtaining first-generation EGFR-TKI resistance. Methods A total number of 1...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Changhui Li, Wei Nie, Jingdong Guo, Anning Xiong, Hua Zhong, Tianqing Chu, Runbo Zhong, Jianlin Xu, Jun Lu, Xiaoxuan Zheng, Bo Zhang, Yinchen Shen, Feng Pan, Baohui Han, Xueyan Zhang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2021-05-01
coleção:	Respiratory Research
Assuntos:	Osimertinib Brain metastases EGFR T790M mutation Radiotherapy
Acesso em linha:	https://doi.org/10.1186/s12931-021-01741-9
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!